Business Context and Reporting Period
Company: Rocket Pharmaceuticals, Inc. (RCKT)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Rocket is a commercial-stage biotechnology company developing genetic therapies for rare diseases. The company operates two primary platforms: in vivo adeno-associated virus (AAV) vectors for cardiovascular diseases and ex vivo lentiviral (LV) vectors for hematologic disorders. In March 2026, the FDA granted accelerated approval for KRESLADI (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency-I (LAD-I). The company has not yet generated revenue from product sales.
Key Financial Metrics
| Metric ($ in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(47,594) | $(61,334) |
| Net Loss Per Share (Basic & Diluted) | $(0.42) | $(0.56) |
| Operating Expenses | $48,511 | $64,388 |
| Research & Development (R&D) | $31,454 | $35,942 |
| General & Administrative (G&A) | $17,057 | $28,446 |
| Cash, Cash Equivalents & Investments | $144,379 | $188,929 |
| Net Cash Used in Operating Activities | $(45,394) | $(55,790) |
| Accumulated Deficit | $(1,488,833) | $(1,279,450) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $15.9 million (24.7%) compared to Q1 2025. This reduction was driven by a strategic corporate reorganization in July 2025, which included a ~30% workforce reduction and the de-prioritization of non-core programs (Fanconi Anemia and Pyruvate Kinase Deficiency).
- R&D Expenses: Decreased by $4.5 million, primarily due to lower manufacturing costs and reduced headcount, partially offset by increased clinical trial expenses for the Danon disease program.
- G&A Expenses: Decreased by $11.4 million, largely due to a $5.7 million reduction in legal expenses (following a 2025 litigation settlement) and lower commercial preparation costs.
- Liquidity: Cash and investments decreased by approximately $44.5 million quarter-over-quarter due to operating cash burn, though investing activities provided a net cash inflow of $17.4 million from investment maturities.
Guidance, Outlook, and Risks
- Capital Runway: Management believes existing cash, investments, and anticipated proceeds from the sale of a Priority Review Voucher (PRV) will fund operations into the second quarter of 2028.
- PRV Sale: In April 2026 (subsequent to the reporting period), the company entered a definitive agreement to sell its PRV for $180 million. This transaction is expected to provide non-dilutive capital to support the cardiovascular pipeline.
- Commercialization: While KRESLADI received FDA approval in March 2026, the company does not expect material revenue in the near term due to the ultra-rare patient population and phased commercial rollout.
- Clinical Updates:
- RP-A501 (Danon Disease): The Phase 2 pivotal study resumed in August 2025 after a clinical hold was lifted. The study is proceeding with a recalibrated lower dose (3.8 x 10^13 GC/kg) following an investigation into serious adverse events (SAEs) linked to a C3 inhibitor in the immunomodulation regimen.
- RP-A601 (PKP2-ACM): Phase 1 study is ongoing with preliminary data showing increased PKP2 protein expression.
- Legal Proceedings: The company is defending against consolidated securities class action lawsuits and a derivative action related to public statements regarding the RP-A501 Phase 2 trial. The company cannot estimate potential losses at this stage.
Investor Verification Checklist
- PRV Closing: Verify the closing status and receipt of the $180 million Priority Review Voucher sale proceeds.
- KRESLADI Commercialization: Monitor treatment center onboarding progress and initial patient dosing timelines to assess revenue generation potential.
- RP-A501 Safety Data: Review upcoming data releases from the resumed Phase 2 trial to confirm the safety profile of the recalibrated dose.
- Litigation Status: Track the outcome of the motion to dismiss the consolidated securities class action lawsuit filed in January 2026.
- Cash Burn Rate: Monitor quarterly cash usage to ensure alignment with the projected runway into 2028.